Perspective Therapeutics (CATX) Depreciation & Amortization (CF) (2010 - 2026)

Perspective Therapeutics has disclosed Depreciation & Amortization (CF) across 13 years of filings, most recently posting $1.1 million for Q2 2026.

• In Q2 2026, Depreciation & Amortization (CF) rose 55.66% year-over-year to $1.1 million; the TTM figure through Jun 2026 stood at $4.1 million (up 42.56% YoY), while the FY2025 annual figure was $3.3 million, up 40.98% from the prior year.
• Depreciation & Amortization (CF) came in at $1.1 million for Q2 2026 at Perspective Therapeutics, up from $1.1 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $1.1 million in Q2 2026 to a low of $74000.0 in Q1 2022.
• Average Depreciation & Amortization (CF) over 5 years is $544117.6, with a median of $572000.0 recorded in 2024.
• Year-over-year, Depreciation & Amortization (CF) soared 158.3% in 2024 and advanced 15.84% in 2025.
• Over 5 years, Depreciation & Amortization (CF) stood at $197000.0 in 2022, then surged by 53.3% to $302000.0 in 2023, then surged by 134.77% to $709000.0 in 2024, then surged by 42.6% to $1.0 million in 2025, then increased by 12.86% to $1.1 million in 2026.
• Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $1.1 million in Q2 2026, $1.1 million in Q1 2026, and $1.0 million in Q4 2025.